Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples